Paul J. Thuluvath

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres et al. · New England Journal of Medicine · 2014 · 1.2K citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection

Tanayott Thaweethai, Sarah E. Jolley, Elizabeth W. Karlson et al. · JAMA · 2023 · 848 citations · Full text

Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +14

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 689 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Liver Transplantation in the United States, 1999-2008

Paul J. Thuluvath, Mary K. Guidinger, John J. Fung et al. · American Journal of Transplantation · 2010 · 577 citations · Full text

Medicine, Surgery, Hepatology +13